

Daftar Pustaka

1. Shin B, Cole SL, Park HY, Kheradmand F. Smoking and the risk of chronic obstructive pulmonary disease exacerbations in the general population: A systematic review. *PLoS One*. 2021;16(4):e0250004.
2. National Cancer Institute. Harms of Cigarette Smoking and Health Benefits of Quitting [Internet]. Updated 2022 [cited 2025 Aug 6]. Available from: <https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/cessation-fact-sheet>
3. Ministry of Health (Indonesia), World Health Organization. Global Adult Tobacco Survey: Indonesia Report 2021. Jakarta: Ministry of Health (Indonesia) and WHO Indonesia; 2024 Aug 22. Available from: <https://www.who.int/indonesia/news/detail/22-08-2024-ministry-of-health-and-who-release-global-adult-tobacco-survey-indonesia-report-2021>
4. Badan Penelitian dan Pengembangan Kesehatan. RISKESDAS 2018: Laporan Nasional. Jakarta: Kementerian Kesehatan RI; 2018.
5. Centers for Disease Control and Prevention. Smoking & Tobacco Use: Fast Facts [Internet]. Atlanta: U.S. Department of Health and Human Services; 2023 [cited 2025 Aug 6]. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm
6. Chubachi S, Yasuda H, Nakayama S, et al. Clinical features of chronic obstructive pulmonary disease with lung cancer: A Japanese cohort study. *Respir Investig*. 2020;58(2):130–7.
7. Jackson SJ, Smith R, Thompson L, et al. Every cigarette reduces life expectancy by approximately 20 minutes: men lose ~17 min, women ~22 min; lifelong smokers lose ~10 years of life. *Addiction*. 2025 Jan; [Study commissioned by University College London and UK Dept of Health and Social Care].
8. Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer: The missing link. *Transl Lung Cancer Res*. 2021;10(1):59–70.
9. Inoue M, Sawada N, Matsuda T, et al. Lung cancer incidence and smoking in Japan: The Japan Public Health Center-based Prospective Study. *Cancer Causes Control*. 2020;31(3):243–50.
10. Ytterstad E, Moe PC, Hjalmarssen A. COPD in patients with lung cancer: Prevalence and mortality. *Int J Chron Obstruct Pulmon Dis*. 2016;11:1839–45.
11. COPD Foundation. COPD linked to higher lung cancer risk among smokers [Internet]. Miami (FL): COPD Foundation; 2016 [cited 2025 Aug 6]. Available from: <https://journal.copdfoundation.org/jcopdf/id/1394/Chronic-Obstructive-Pulmonary-Disease-and-Lung-Cancer-A-Review-for-Clinicians>

12. Zhao G, Li X, Lei S, et al. Prevalence of lung cancer in chronic obstructive pulmonary disease: A systematic review and meta analysis. *Front Oncol.* 2022;12:947981. doi:10.3389/fonc.2022.947981
13. Houghton AM. Mechanistic links between COPD and lung cancer. *Nat Rev Cancer.* 2013;13(4):233–45.
14. Fathana PB, Wicaksono AS, Ernawati DS. Profil Klinis Pasien Kanker Paru dengan PPOK di RSUP Persahabatan. *Jurnal Respirologi Indonesia.* 2019;39(1):23–30.
15. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD: 2023 Report. [Internet]. GOLD; 2023. Available from: <https://goldcopd.org>
16. Hou Y, Zhou Y, Wang Y, Zhang Y, Zhang Y, Liu H, et al. Cigarette smoking and lung cancer risk in China: a meta-analysis of case-control studies. *Asian Pac J Cancer Prev.* 2016;17(2):867–72.
17. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. *Eur Respir J.* 2017;50(3):1700684.
18. De Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Pinto-Plata V, et al. Lung cancer in patients with chronic obstructive pulmonary disease— incidence and predicting factors. *Am J Respir Crit Care Med.* 2020;182(8):913–9.
19. Zhai R, Yu X, Shao J, Yu L. Comprehensive management of COPD in lung cancer patients. *Front Oncol.* 2021;11:658620.
20. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD): Key facts [Internet]. WHO; 2023. Available from: [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))
21. Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis. *Lancet.* 2020;396(10258):1204–22.
22. Adigun R, Gupta V, Sharma S. Chronic Obstructive Pulmonary Disease (COPD). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559280/>
23. Perhimpunan Dokter Paru Indonesia. Pedoman Diagnosis dan Penatalaksanaan Penyakit Paru Obstruktif Kronik (PPOK). Edisi Revisi. Jakarta: PDPI; 2016.
24. Blanco, I., Diego, I., Bueno, P., Casas-Maldonado, F., & Miravittles, M. (2019). Distribusi geografis prevalensi PPOK di dunia yang ditampilkan oleh peta Sistem Informasi Geografis. *European Respiratory Journal*
25. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and

- mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49.
26. GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet*. 2021;397(10292):2337–2360.
 27. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United States. 2021. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
 28. World Health Organization. WHO global report on trends in prevalence of tobacco use 2000–2025, 3rd edition. Geneva: WHO; 2019.
 29. Li Y, Hecht SS. Carcinogenic components of tobacco and tobacco smoke: a 2022 update. *Food Chem Toxicol*. 2022;165:113179.
 30. Budnevsky AV, et al. Oxidative stress in COPD: pathogenetic and clinical aspects. *Oxid Med Cell Longev*. 2021;2021:6644002.
 31. Sotgia S, et al. Blood glutathione redox state in COPD: a meta-analysis. *Antioxidants (Basel)*. 2020;9(11):1146.
 32. Pandey G, et al. Protective role of Nrf2 pathway against oxidative stress in COPD. *Front Med*. 2025;12:1492256.
 33. Smith CJ, et al. Epigenetic regulation and cigarette smoke: impact on COPD and lung cancer. *Transl Lung Cancer Res*. 2023;12(2):200–215.
 34. IARC. World Cancer Report: Cancer Research for Cancer Prevention. Lyon: International Agency for Research on Cancer; 2020.
 35. Shin SH, Lee J, Kim Y, et al. Smoking Reduction and Risk of Lung Cancer and Cardiopulmonary Outcomes in COPD: A National Cohort Study. *Respir Res*. 2024;25(1):133.
 36. Liang Y, Liu Y, Tian Y, Wang Z, Wang Y. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. *Lung Cancer*. 2020;147:21–27. doi:10.1016/j.lungcan.2020.06.006.
 37. Torres-Durán M, Abal-Arca J, Golpe-Gómez R, Fernández-Villar A, Ruano-Ravina A. Chronic obstructive pulmonary disease and lung cancer risk: the BODE index as a prognostic factor. *Respiratory Medicine*. 2020;165:105932. <https://doi.org/10.1016/j.rmed.2020.105932>
 38. Sánchez-Salcedo P, Wilson DO, de-Torres JP, Campo A, Alcaide AB, García-Granero M, et al. Improving selection criteria for lung cancer screening. The potential role of COPD. *Chest*. 2015;147(6):1619–26. <https://doi.org/10.1378/chest.14-1311>
 39. Zhang J, Chen D, Wang C, Zhu L, Zhao Q. Association between chronic obstructive pulmonary disease and lung cancer: a meta-analysis based on East

- Asian population. *Frontiers in Medicine*. 2021;8:684113. <https://doi.org/10.3389/fmed.2021.684113>
40. Budnevsky AV, Yablonsky PK, Zhidkov IL, Gvozdenko TA. COPD heterogeneity: implications for management. *Multidiscip Respir Med*. 2016;11:14. doi:10.1186/s40248-016-0053-4.
 41. Miravittles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. *Arch Bronconeumol*. 2022;58(1):69-81. doi:10.1016/j.arbres.2021.12.010.
 42. Pleguezuelos E, Soriano JB, López-Campos JL, Gonzalez-Moro JM, Alonso A, Miravittles M. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. *Eur Respir J*. 2018;41(6):1252–1263. doi:10.1183/13993003.01152-2017.
 43. Houghton, A.M. (2018). Mekanisme umum yang menghubungkan penyakit paru obstruktif kronis dan kanker paru. *Annals of the American Thoracic Society*, 15(4), S273–S277.
 44. Yang L, Chen Y, Li X, et al. Association of emphysema detected on low-dose CT scan with the risk of lung cancer in patients with COPD: a population-based cohort study. *BMC Pulm Med*. 2022;22(1):87. doi:10.1186/s12890-022-01863-y
 45. Zhang J, Zhang Y, Li Y, et al. Association between emphysema and lung cancer in COPD patients: a systematic review and meta-analysis. *Respir Res*. 2022;23(1):26.
 46. Kinsey CM, San Jose Estepar R, Van Beek EJR, et al. Severity of emphysema predicts location of lung cancer. *Chest*. 2016;149(2):475–485. doi:10.1378/chest.15-0032
 47. Bakhru MR, Boulanger LE, Kaup T, et al. Emphysema detected on CT and lung cancer risk: a systematic review and meta-analysis. *Respir Med*. 2022;183:106427. doi:10.1016/j.rmed.2021.106427
 48. Brenner DR, Hung RJ, Boffetta P, et al. Chronic bronchitis and lung cancer risk: SYNERGY study findings. *Am J Epidemiol*. 2021;190(4):650–658. doi:10.1093/aje/kwaa207
 49. Brown LM, Patel M, Zhang Z, et al. Oxidative stress and chromatin dynamics in COPD progression. *Antioxid Redox Signal*. 2017;27(11):995–1010
 50. Johnson K, Li Y, Chen C, et al. Emerging biological mechanisms linking COPD and lung cancer: inflammation, EMT, and extracellular matrix remodeling. *Biomedicines*. 2023;11(7):1854.
 51. Grose D, Morrison DS, Devereux G, et al. Comorbidities in lung cancer: prevalence, severity and links with treatment outcomes. *BMC Cancer*. 2020;20:952.

52. Ghosh S, Deaken ZE, Miller MR, et al. Genetic susceptibility and alpha-1 antitrypsin deficiency in COPD and lung cancer: a systematic review and meta-analysis. *Respir Res.* 2019;20(1):133.
53. Tubío-Pérez O, Pineda-Lucena A, Casas-Álvarez B, et al. Alpha-1 antitrypsin deficiency increases lung cancer risk in COPD patients: results from a multicenter cohort. *Biomedicines.* 2023;11(7):1854.
54. Lee S, Kim HJ, Park JK, et al. Genetic loci shared between COPD and lung cancer: insights from recent GWAS. *Cell Mol Life Sci.* 2021;78(14):5779–5792.
55. Johnson K, Li Y, Chen C, et al. Inflammation-driven epigenetic remodeling and signaling deregulation in COPD related lung cancer. *Biomedicines.* 2023;11(7):1982.
56. Gonçalves MD, Hopkins BD, Cantley LC. Replicative senescence: mechanistic insights and recent developments. *Nat Rev Mol Cell Biol.* 2019;20(5):277–291.
57. American Lung Association. COPD Causes and Risk Factors. 2020. Available from: <https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/what-causes-copd>
58. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. *Clin Chest Med.* 2014;35(1):71–86.
59. Tiku V, Jain C, Razdan R. Mitochondrial Dysfunction in Chronic Obstructive Pulmonary Disease and Lung Cancer. *Cells.* 2022;11(20):3196. Published 2022 Oct 15. doi:10.3390/cells11203196
60. Phillips DH. DNA adducts as markers of exposure and risk. *Mutat Res Genet Toxicol Environ Mutagen.* 2020;783:108285.
61. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and DNA damage in humans: a meta-analysis. *Mutagenesis.* 2019;34(5–6):475–87.
62. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. *Nat Rev Cancer.* 2022;22(3):193–207.
63. Rydberg P, Glatt H. Detoxification of polycyclic aromatic hydrocarbons by human glutathione S-transferases. *Arch Toxicol.* 2021;95(1):43–53.
64. Balbo S, James-Yi S, Johnson CS, et al. DNA adducts derived from tobacco carcinogens: a tool for measuring cancer risk. *Chem Res Toxicol.* 2020;33(5):1129–50.
65. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance of p53 mutations in lung cancer. *Nature.* 2017;545(7652):526–30.
66. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat Rev Mol Cell Biol.* 2020;21(7):363–83.
67. Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem Biol Interact.* 2021;345:109576.

68. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? *Free Radic Biol Med*. 2017;49(11):1603–16.
69. Qu Y, Han B, Yu Y, Yao L, Ma L, Wu Z. Hypoxia-inducible factor 1- α (HIF-1 α) in COPD and lung cancer: A potential therapeutic target. *Int J Chron Obstruct Pulmon Dis*. 2020;15:3207–16.
70. Willis BC, Borok Z. TGF- β -induced EMT: mechanisms and implications for fibrotic lung disease. *Am J Physiol Lung Cell Mol Physiol*. 2019;297(3):L452–L463. doi:10.1152/ajplung.00019.2009
71. Gao Y, Li X, Xu X, et al. Galectin-3 expression and its role in airway inflammation in chronic obstructive pulmonary disease. *Am J Physiol Lung Cell Mol Physiol*. 2019;316(1):L105–L114. doi:10.1152/ajplung.00307.2018
72. Travis MA, Sheppard D. TGF- β activation and function in immunity. *Annu Rev Immunol*. 2019;32:51–82. doi:10.1146/annurev-immunol-032713-120257
73. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest*. 2020;120(5):1786–93. doi:10.1172/JCI42295
74. De Caterina R, Amici A, Iezzi A, et al. COX-2 inhibitors and cancer prevention: is aspirin still the benchmark? *Curr Atheroscler Rep*. 2017;19(11):45. doi:10.1007/s11883-017-0705-7
75. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. *Clin Lung Cancer*. 2019;10(5):307–12. doi:10.3816/CLC.2019.n.003
76. Lee J, Park S, Kim Y, et al. Prognostic significance of COPD in non-small-cell lung cancer patients. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1457–65.
77. Yao H, Li X, Zhang J, et al. Influence of COPD on postoperative outcomes in early-stage lung cancer patients undergoing lobectomy. *J Thorac Dis*. 2019;11(9):3752–60.
78. Sekine Y, Yamada Y, Chiyo M, et al. Impact of COPD on postoperative complications and long-term survival in patients with NSCLC. *Lung Cancer*. 2016;94:57–61.
79. Li Y, Xiao X, Liu J, et al. Effect of pre-existing COPD on survival of patients with early-stage non-small-cell lung cancer after surgery. *BMC Pulm Med*. 2021;21(1):94.
80. Wang Y, Xu J, Meng Y, et al. Correlation between severity of emphysema in COPD and histologic subtypes of lung cancer. *Respir Res*. 2019;20(1):192. doi:10.1186/s12931-019-1139-2
81. Sekine Y, Yamada Y, Chiyo M, et al. The impact of COPD on histological subtypes of lung cancer. *Respir Investig*. 2016;54(3):180–4. doi:10.1016/j.resinv.2015.12.002

82. Suzuki M, Makita H, Konno S, et al. COPD assessment test and severity of airflow limitation in relation to lung cancer risk in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1247–54. doi:10.2147/COPD.S245937
83. Zhang Y, Li Y, Wang J, Zhang X, Ma J, Zhao H. Impact of COPD severity on the stage at diagnosis and prognosis of non-small cell lung cancer: A retrospective study. *Transl Lung Cancer Res*. 2022;11(4):639–648. doi:10.21037/tlcr-21-1076
84. Lee JH, Lim JU, Choi SE, Hwang YI, Park JS, Kim DK, et al. Clinical impact of COPD group classification on the diagnosis and staging of lung cancer. *Eur Respir J*. 2022;60(6):2200795. doi:10.1183/13993003.00795-2022
85. Gao Y, Zhang Y, Liu Q, Xu L, Chen M, Duan H. The impact of chronic obstructive pulmonary disease on the survival of patients with non-small cell lung cancer: a meta-analysis. *J Thorac Dis*. 2020;12(3):1100-1112. doi:10.21037/jtd.2019.12.114
86. Kiriakopoulos E, Tsoukalas N, Kiagia M, Syrigos K. Comorbid COPD in Lung Cancer: A Comprehensive Review of Mechanisms, Treatment, and Outcomes. *J Clin Med*. 2022;11(9):2391. doi:10.3390/jcm11092391
87. Mao Y, Zhang Y, Dong L, Li X, Zhang Y. COPD and lung cancer: A meta-analysis based on prospective cohort studies. *Lung Cancer*. 2017 Feb;112:140–5. doi:10.1016/j.lungcan.2017.08.024.